Thomas G.P. Bumm

1.8k total citations
24 papers, 1.3k citations indexed

About

Thomas G.P. Bumm is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Thomas G.P. Bumm has authored 24 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 14 papers in Hematology and 11 papers in Rheumatology. Recurrent topics in Thomas G.P. Bumm's work include Chronic Myeloid Leukemia Treatments (12 papers), Eosinophilic Disorders and Syndromes (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Thomas G.P. Bumm is often cited by papers focused on Chronic Myeloid Leukemia Treatments (12 papers), Eosinophilic Disorders and Syndromes (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Thomas G.P. Bumm collaborates with scholars based in United States, Germany and Austria. Thomas G.P. Bumm's co-authors include Michael W. Deininger, Brian Druker, Marc Loriaux, Lisa J. Wood, Jutta Deininger, Amie S. Corbin, Karl J. Aichberger, Richard T. Silver, Thomas O’Hare and Ralf C. Bargou and has published in prestigious journals such as Blood, Molecular and Cellular Biology and Cancer Research.

In The Last Decade

Thomas G.P. Bumm

22 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas G.P. Bumm United States 13 819 771 468 428 336 24 1.3k
Pierre Laneuville Canada 18 487 0.6× 747 1.0× 282 0.6× 229 0.5× 297 0.9× 57 1.1k
George F. Barker United States 6 470 0.6× 924 1.2× 713 1.5× 376 0.9× 260 0.8× 7 1.6k
Gabriele Gugliotta Italy 20 704 0.9× 857 1.1× 246 0.5× 377 0.9× 160 0.5× 60 1.1k
G Grosveld Netherlands 8 761 0.9× 1.1k 1.5× 441 0.9× 293 0.7× 202 0.6× 13 1.5k
J V Melo United Kingdom 16 644 0.8× 553 0.7× 280 0.6× 184 0.4× 188 0.6× 26 1.1k
Stephane Wong United States 11 339 0.4× 495 0.6× 349 0.7× 179 0.4× 139 0.4× 15 802
Ulla Olsson‐Strömberg Sweden 21 608 0.7× 865 1.1× 366 0.8× 260 0.6× 439 1.3× 53 1.5k
N Philippe France 13 626 0.8× 1.1k 1.4× 545 1.2× 231 0.5× 213 0.6× 33 1.5k
Tinisha McDonald United States 12 372 0.5× 868 1.1× 753 1.6× 138 0.3× 543 1.6× 30 1.7k
Daniel W. Sherbenou United States 16 381 0.5× 587 0.8× 349 0.7× 199 0.5× 289 0.9× 40 911

Countries citing papers authored by Thomas G.P. Bumm

Since Specialization
Citations

This map shows the geographic impact of Thomas G.P. Bumm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas G.P. Bumm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas G.P. Bumm more than expected).

Fields of papers citing papers by Thomas G.P. Bumm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas G.P. Bumm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas G.P. Bumm. The network helps show where Thomas G.P. Bumm may publish in the future.

Co-authorship network of co-authors of Thomas G.P. Bumm

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas G.P. Bumm. A scholar is included among the top collaborators of Thomas G.P. Bumm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas G.P. Bumm. Thomas G.P. Bumm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rogoll, Dorothee, Laura‐Sophie Landwehr, Jochen Schreiner, et al.. (2025). World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC. European Journal of Endocrinology. 193(3). 359–373.
2.
3.
Einsele, Hermann, et al.. (2021). Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. Communications Biology. 4(1). 44–44. 12 indexed citations
4.
Braig, Friederike, Anna Brandt, Mariele Goebeler, et al.. (2016). Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 129(1). 100–104. 190 indexed citations
5.
Andrulis, Mindaugas, Simone S. Riedel, Thorsten Stühmer, et al.. (2012). The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. British Journal of Haematology. 160(4). 465–476. 54 indexed citations
6.
Fuji, Shigeo, Julia Fischer, Markus Kapp, et al.. (2012). Wilms Tumor Protein-1-Derived 9-Mer Peptide Induces CD4 T-Cell Responses in an HLA-DR Restricted Manner. Blood. 120(21). 4351–4351. 2 indexed citations
7.
Stühmer, Thorsten, Zhenhai Gao, Thomas G.P. Bumm, et al.. (2012). Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.. PubMed. 32(2). 453–62. 14 indexed citations
8.
Fleischman, Angela G., Karl J. Aichberger, Curtis L. Petersen, et al.. (2010). Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm. Blood. 116(21). 795–795. 1 indexed citations
9.
Tyner, Jeffrey, Thomas G.P. Bumm, Jutta Deininger, et al.. (2010). CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 115(25). 5232–5240. 183 indexed citations
10.
Sherbenou, Daniel W., Oliver Hantschel, Ines Kaupe, et al.. (2010). BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 116(17). 3278–3285. 63 indexed citations
11.
Aichberger, Karl J., Angela G. Fleischman, Thomas G.P. Bumm, et al.. (2009). Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.. Blood. 114(22). 2917–2917.
12.
Sherbenou, Daniel W., Oliver Hantschel, Ines Kaupe, et al.. (2008). Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 22(6). 1184–1190. 31 indexed citations
13.
Agarwal, Anupriya, Thomas G.P. Bumm, Amie S. Corbin, et al.. (2008). Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease. Blood. 112(5). 1960–1970. 54 indexed citations
14.
Bumm, Thomas G.P., Jeffrey Tyner, Jutta Deininger, et al.. (2008). Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD. Blood. 112(11). 856–856. 3 indexed citations
15.
Bumm, Thomas G.P., Collin Elsea, Amie S. Corbin, et al.. (2006). Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease. Cancer Research. 66(23). 11156–11165. 151 indexed citations
16.
MacPartlin, Mary, Thomas O’Hare, Thomas G.P. Bumm, et al.. (2006). Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib.. Blood. 108(11). 4796–4796. 2 indexed citations
17.
Griswold, Ian J., Mary MacPartlin, Thomas G.P. Bumm, et al.. (2006). Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib. Molecular and Cellular Biology. 26(16). 6082–6093. 152 indexed citations
18.
Bumm, Thomas G.P., Collin Elsea, Lisa G. Wood, et al.. (2005). JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice.. Blood. 106(11). 376–376. 1 indexed citations
19.
Griswold, Ian J., Thomas G.P. Bumm, Thomas O’Hare, et al.. (2004). Investigation of the Biological Differences between Bcr-Abl Kinase Mutations Resistant to Imatinib.. Blood. 104(11). 555–555. 3 indexed citations
20.
Bumm, Thomas G.P., Haifa Kathrin Al‐Ali, Knut Krohn, et al.. (2003). Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 101(5). 1941–1949. 138 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre Laneuville Breakdown of academic impact, for papers by George F. Barker Breakdown of academic impact, for papers by Gabriele Gugliotta Breakdown of academic impact, for papers by G Grosveld Breakdown of academic impact, for papers by J V Melo Breakdown of academic impact, for papers by Stephane Wong Breakdown of academic impact, for papers by Ulla Olsson‐Strömberg Breakdown of academic impact, for papers by N Philippe Breakdown of academic impact, for papers by Tinisha McDonald Breakdown of academic impact, for papers by Daniel W. Sherbenou
Rankless by CCL
2026